Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:51 PM
Ignite Modification Date:
2025-12-24 @ 11:51 PM
NCT ID:
NCT06161051
Eligibility Criteria:
Inclusion Criteria:
* Patient was aged ≥ 18 years at the time of NSCLC diagnosis.
* Had histologically confirmed advanced (stage IIIB, IIIC, or IV) NSCLC with MET exon 14 skipping mutation.
* Initiated first-line (1L) treatment for aNSCLC between 1 January 2017 and date of data abstraction with one of the following treatment regimen:
* Capmatinib
* IO agent in monotherapy (e.g., atezolizumab, pembrolizumab)
* CT regimen, single agent or combinations of CT agents (e.g., platinum agents, taxane agents, gemcitabine, pemetrexed)
* Combination regimen containing IO and CT agents
* Had ≥ 6 months of potential follow-up time after the initiation of 1L treatment for aNSCLC, except if the patient died sooner.
* Living or deceased at the time of chart abstraction.
Exclusion Criteria:
* Presence of other mutations (e.g., EGFR, ALK, ROS1, RET, NTRK, BRAF, or KRAS) at any time.
* Treatment with other MET inhibitors such as crizotinib or tepotinib at any time during the study period.
* Participation in clinical trials related to treatment for NSCLC at any timepoint.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06161051
Study Brief:
Protocol Section:
NCT06161051